iShares Nasdaq Biotechnology Index Fund stock performance trend indicates that the stock price has rallied 8.43% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 2.01% . Looking at the past 52 week period, the stock price is up at 17.48% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of iShares Nasdaq Biotechnology Index Fund has a positive value of 3.78 compared to overall market. iShares Nasdaq Biotechnology ETF is having a Relative Strength Index of 51.52 which indicates the stock is not yet over sold or over bought based on the technical indicators.
iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has tumbled 1.77% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.32% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2%. iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has underperformed the index by 0.83% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) stock ended Friday session in the red zone in a volatile trading. The stock closed down 3.31 points or 1.11% at $295.28 with 1,702,162 shares getting traded. Post opening the session at $293.75, the shares hit an intraday low of $293.57 and an intraday high of $297.075 and the price was in this range throughout the day. The company has a market cap of $8,652 million and the number of outstanding shares has been calculated to be 29,300,000 shares. The 52-week high of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) is $303.74 and the 52-week low is $240.3.
The ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.